Upfront licensing costs hit a five year high

Licensing is the life blood of biopharma, or so the saying goes, and activity across the past five years shows a steady flow of these types of deals.

A closer look at the data, from Evaluate Pharma, shows that the median up-front fee hit a five year high in the second half of 2021. But in the same period, the number of transactions hit a five year low.